Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics, Inc. filed a current report to note that it has released its financial results for the three months ended September 30, 2025. The company furnished a press release titled “4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” as Exhibit 99.1. The filing indicates that the release also covers recent operational developments and outlines milestones the company expects in the future.
4D Molecular Therapeutics (FDMT) completed an underwritten equity offering, issuing 8,385,809 shares of common stock at $10.51 per share and pre-funded warrants for 1,128,949 shares at $10.5099 per warrant. The company reported net proceeds of approximately $93.3 million after underwriting discounts and expenses, and the transaction closed on November 7, 2025.
Underwriters purchased the shares at $9.8794 and the pre-funded warrants at $9.8793. The offering was conducted via a prospectus supplement under FDMT’s Form S-3 (effective August 15, 2023). Directors and executive officers agreed to a lock-up through January 6, 2026, subject to customary exceptions.
4D Molecular Therapeutics (FDMT) launched a primary offering of 8,385,809 shares and pre-funded warrants to purchase 1,128,949 shares at $10.51 and $10.5099, respectively. The total offering price is $99,999,993, less $6,000,006 in underwriting discounts, yielding $93,999,987 in proceeds before expenses and estimated net proceeds of approximately $93.3 million.
The company plans to fund research and development and commercialization preparations, and, together with existing cash of $372.2 million as of September 30, 2025 and expected Otsuka payments, projects funding at least into the second half of 2028. FDMT also announced an Otsuka collaboration granting APAC rights to 4D-150 with an $85.0 million upfront payment, up to $335.5 million in milestones, and tiered double‑digit royalties. Shares outstanding were 46,700,242 as of June 30, 2025.
4D Molecular Therapeutics (FDMT) launched a primary offering of 8,385,809 shares and pre-funded warrants to purchase 1,128,949 shares at $10.51 and $10.5099, respectively. The total offering price is $99,999,993, less $6,000,006 in underwriting discounts, yielding $93,999,987 in proceeds before expenses and estimated net proceeds of approximately $93.3 million.
The company plans to fund research and development and commercialization preparations, and, together with existing cash of $372.2 million as of September 30, 2025 and expected Otsuka payments, projects funding at least into the second half of 2028. FDMT also announced an Otsuka collaboration granting APAC rights to 4D-150 with an $85.0 million upfront payment, up to $335.5 million in milestones, and tiered double‑digit royalties. Shares outstanding were 46,700,242 as of June 30, 2025.
4D Molecular Therapeutics (FDMT) launched a primary offering of 8,385,809 shares and pre-funded warrants to purchase 1,128,949 shares at $10.51 and $10.5099, respectively. The total offering price is $99,999,993, less $6,000,006 in underwriting discounts, yielding $93,999,987 in proceeds before expenses and estimated net proceeds of approximately $93.3 million.
The company plans to fund research and development and commercialization preparations, and, together with existing cash of $372.2 million as of September 30, 2025 and expected Otsuka payments, projects funding at least into the second half of 2028. FDMT also announced an Otsuka collaboration granting APAC rights to 4D-150 with an $85.0 million upfront payment, up to $335.5 million in milestones, and tiered double‑digit royalties. Shares outstanding were 46,700,242 as of June 30, 2025.
4D Molecular Therapeutics (FDMT) reported a preliminary cash, cash equivalents and marketable securities balance of $372.2 million as of September 30, 2025. The company also announced positive interim 1.5–3.5-year data from its Phase 1/2 PRISM trial of 4D-150 in wet age-related macular degeneration.
Across cohorts, patients showed sustained reductions in supplemental anti-VEGF injections after 4D-150. In the Phase 2b recently diagnosed subgroup (Phase 3 comparable), mean supplemental injections were reduced 94% through year 1 and 92% through year 1.5. The broader Phase 2b cohort showed 83% through year 1 and 82% through year 1.5, while the Phase 1/2a severe, recalcitrant cohort showed 83% through year 1 and 79% through year 2. By 6‑month segments, the Phase 2b recently diagnosed subgroup recorded mean injections per patient of 0.1 (months 0–6), 0.2 (6–12), and 0.4 (12–18).
4D Molecular Therapeutics (FDMT) reported a preliminary cash, cash equivalents and marketable securities balance of $372.2 million as of September 30, 2025. The company also announced positive interim 1.5–3.5-year data from its Phase 1/2 PRISM trial of 4D-150 in wet age-related macular degeneration.
Across cohorts, patients showed sustained reductions in supplemental anti-VEGF injections after 4D-150. In the Phase 2b recently diagnosed subgroup (Phase 3 comparable), mean supplemental injections were reduced 94% through year 1 and 92% through year 1.5. The broader Phase 2b cohort showed 83% through year 1 and 82% through year 1.5, while the Phase 1/2a severe, recalcitrant cohort showed 83% through year 1 and 79% through year 2. By 6‑month segments, the Phase 2b recently diagnosed subgroup recorded mean injections per patient of 0.1 (months 0–6), 0.2 (6–12), and 0.4 (12–18).
4D Molecular Therapeutics (FDMT) reported a preliminary cash, cash equivalents and marketable securities balance of $372.2 million as of September 30, 2025. The company also announced positive interim 1.5–3.5-year data from its Phase 1/2 PRISM trial of 4D-150 in wet age-related macular degeneration.
Across cohorts, patients showed sustained reductions in supplemental anti-VEGF injections after 4D-150. In the Phase 2b recently diagnosed subgroup (Phase 3 comparable), mean supplemental injections were reduced 94% through year 1 and 92% through year 1.5. The broader Phase 2b cohort showed 83% through year 1 and 82% through year 1.5, while the Phase 1/2a severe, recalcitrant cohort showed 83% through year 1 and 79% through year 2. By 6‑month segments, the Phase 2b recently diagnosed subgroup recorded mean injections per patient of 0.1 (months 0–6), 0.2 (6–12), and 0.4 (12–18).
4D Molecular Therapeutics (FDMT) announced a collaboration and license agreement with Otsuka Pharmaceutical granting Otsuka exclusive rights to develop and commercialize 4D-150 for ophthalmological diseases in Japan, China, Australia and other APAC markets. The Company will continue to lead all Phase 3 clinical activity globally, while Otsuka will lead regulatory and commercialization in its territories.
Financial terms include an $85 million upfront cash payment, expected cost sharing of at least $50 million over the next three years for global development, eligibility for up to $335.5 million in potential regulatory and commercial milestones, and tiered double-digit royalties on net sales in Otsuka’s territories. 4DMT retains full rights outside APAC, including the U.S., Latin America and Europe.
Operationally, APAC sites in 4FRONT-2 (global Phase 3 in wet AMD) are expected to open by year-end, with Japan sites expected to open in January 2026. Enrollment in 4FRONT-1 continues to exceed initial expectations, with over 200 patients randomized as of October 30, 2025. The agreement includes customary governance via a joint steering committee and standard termination and indemnity provisions.
4D Molecular Therapeutics (FDMT) reported an insider transaction by its Chief Legal Officer. On 10/24/2025, the officer exercised 1,084 stock options at $6.49 per share and sold 2,678 common shares at $12 per share under a Rule 10b5-1 plan adopted on June 6, 2025.
Following these transactions, the officer beneficially owned 3,594 common shares directly. The filing also shows 9,295 stock options beneficially owned after the reported activity, with the option grant expiring on 06/17/2032 and vesting monthly from the June 16, 2022 commencement date until the fourth anniversary.
4D Molecular Therapeutics (FDMT) Form 4: the Chief Legal Officer reported an option exercise and a same‑day sale on 10/16/2025. The insider exercised 1,635 stock options at $4.14 per share (Code M) and sold 1,635 common shares at $10.17 per share (Code S) pursuant to a Rule 10b5‑1 plan adopted on June 6, 2025.
Following these transactions, the insider reported 5,188 common shares directly owned and 76,865 derivative securities (stock options) beneficially owned. The exercised option was part of an award vesting monthly in 1/48th increments starting March 6, 2025, with full vesting on the fourth anniversary, and carries an expiration date of March 5, 2035.
4D Molecular Therapeutics (FDMT) reported an insider transaction on a Form 4. The company’s Chief Legal Officer sold 2,408 shares of common stock at $10 on October 9, 2025, pursuant to a Rule 10b5-1 trading plan adopted on June 6, 2025.
Following the sale, the reporting person beneficially owned 5,188 shares, held directly. The filing was made by one reporting person.
4D Molecular Therapeutics (FDMT) filed a Form 3 reporting the initial holdings of its VP, Finance and Controller as of 09/30/2025. The officer directly holds 45,662 shares of common stock. Derivative awards include stock options for 27,700 shares at $22.69 expiring 07/08/2034 and 7,056 shares at $4.14 expiring 03/05/2035. Restricted stock units total 13,850 and 3,528 shares, with vesting schedules beginning on June 20, 2025, subject to continued service.
4D Molecular Therapeutics reported two corporate governance updates. The Board appointed Ashoo Gupta, age 49, as the company’s Principal Financial Officer and Principal Accounting Officer, effective September 30, 2025. He has been Vice President, Finance & Controller since June 2024 and previously held senior finance and controller roles at Kyverna Therapeutics and Myovant Sciences. He will enter into the company’s standard indemnification agreement.
The Board also approved amended and restated bylaws on September 30, 2025. The changes include updates to the advance notice procedures for stockholder proposals of business and for the nomination of directors at meetings. The full text of the amended and restated bylaws is filed as an exhibit and incorporated by reference.